E
Eivind Berge
Researcher at Oslo University Hospital
Publications - 175
Citations - 8630
Eivind Berge is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Stroke & Modified Rankin Scale. The author has an hindex of 36, co-authored 173 publications receiving 6709 citations. Previous affiliations of Eivind Berge include University of Oslo & University of Nottingham.
Papers
More filters
Journal ArticleDOI
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Peter Sandercock,Joanna M. Wardlaw,Richard I. Lindley,Martin Dennis,Geoff Cohen,Gordon D Murray,Karen Innes,Graham Venables,Anna Członkowska,Adam Kobayashi,Stefano Ricci,Veronica Murray,Eivind Berge,Karsten Bruins Slot,Graeme J. Hankey,Manuel Correia,André Peeters,Karl Matz,P. A. Lyrer,Gord Gubitz,Stephen J. Phillips,Antonio Arauz +21 more
TL;DR: For the types of patient recruited in IST-3, despite the early hazards, thrombolysis within 6 h improved functional outcome and benefit did not seem to be diminished in elderly patients.
Journal ArticleDOI
Thrombolysis for acute ischaemic stroke
TL;DR: Thrombolytic therapy, mostly administered up to six hours after ischaemic stroke, significantly reduced the proportion of participants who were dead or dependent at three to six months after stroke and increased the risk of symptomatic intracranial haemorrhage.
Journal ArticleDOI
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
Joanna M. Wardlaw,Veronica Murray,Eivind Berge,Gregory J. del Zoppo,Peter Sandercock,Richard L Lindley,Geoff Cohen +6 more
TL;DR: The evidence indicates that intravenous rt-PA increased the proportion of patients who were alive with favourable outcome and alive and independent at final follow-up, which strengthens previous evidence to treat patients as early as possible after acute ischaemic stroke, although some patients might benefit up to 6 h after stroke.
Journal ArticleDOI
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial
Else Charlotte Sandset,Else Charlotte Sandset,Philip M.W. Bath,Gudrun Boysen,Dalius Jatuzis,Janika Kõrv,Stephan Luders,Gordon D Murray,P. Richter,Risto O. Roine,Andreas Terént,Vincent Thijs,Eivind Berge +12 more
TL;DR: There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure and there was no evidence of a differential effect in any of the prespecified subgroups.
Journal ArticleDOI
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.
Eivind Berge,William Whiteley,Heinrich J. Audebert,Gian Marco De Marchis,Ana Catarina Fonseca,Chiara Padiglioni,Natalia Pérez de la Ossa,Daniel Strbian,Georgios Tsivgoulis,Georgios Tsivgoulis,Guillaume Turc,Guillaume Turc +11 more
TL;DR: The European Stroke Organisation (ESO) guidelines provide evidence-based recurrence guidelines for patients with acute ischaemic stroke as mentioned in this paper, where intrvenous thrombolysis is the only approved systemic reperfusion treatment.